Technologies

AIDD is an integrated tool and a radically new way to discovery new drugs for neurodegenerative diseases (Alzheimer’s, Epilepsy, Ageing, etc.).

Mergers e Acquisitions represent important forms of business deals because of the volumes involved in the transactions and the role of the innovation activity of companies. By considering the patent activity of about one thousand companies, we develop a method to predict future acquisitions by assuming that companies deal more frequently with technologically related ones.

Plants can compete favorably with traditional expression systems (mammalian cells, yeasts or bacteria) to produce recombinant proteins/peptides of pharmaceutical/industrial/agrifood interest. This technology names “Plant Molecular Farming”. The CNR-IBBA research team offers the study of new strategies for the expression and optimization of recombinant proteins/peptides in plant-based systems (plant tissues, transgenic plants, plant cell culture). Our pipeline is based on the following modules:

The environment as well as the food production provide a number of both natural and synthetic compounds whose effects on human being as an organism have not yet been determined nor investigated.

Recently, it has been demonstrated that Raman spectroscopy can play a fundamental role in assisting the work of the anatomopathologist by allowing classification of oncological samples with practically 100% accuracy in oncological diagnosis.

To the enterprises working in the field of nutrition/nutraceutics and drug development/repositioning, we offer the know-how and state-of-the-art instrumentation of our labs to monitor multiple relevant biological parameters at the cellular level: metabolic activity, vitality, health, but also stress and toxicity. The use of advanced imaging techniques based on fluorescent/bioluminescent probes together with the availability of time-lapse acquisitions, guarantee the cutting-edge analysis of different biological parameters over time.